Functionalized carbon dots with guanidine salt ionic liquid regulate oxidative damage and amyloid aggregation.

Area of Science:

• Neuroscience
• Materials Science
• Biochemistry

Background:

• Alzheimer's disease (AD) is characterized by an imbalanced brain microenvironment, including oxidative stress and beta-amyloid (Aβ) accumulation.
• Current therapeutic strategies for AD often target single pathological pathways, highlighting the need for multi-target approaches.

Purpose of the Study:

• To develop a novel therapeutic agent, CDs@TGM-IL, capable of simultaneously mitigating Aβ aggregation and scavenging reactive oxygen species (ROS) in the context of AD.
• To evaluate the efficacy and biocompatibility of CDs@TGM-IL for potential Alzheimer's disease treatment.

Main Methods:

• Synthesis of guanidine salt ionic liquid functionalized carbon dots (CDs@TGM-IL).
• In vitro assessment of CDs@TGM-IL's ability to inhibit Aβ42 aggregation, disaggregate Aβ42 fibrils, and scavenge ROS.
• In vivo evaluation of CDs@TGM-IL's blood-brain barrier (BBB) penetration and cognitive effects in AD mouse models.

Main Results:

• CDs@TGM-IL demonstrated significant inhibition of Aβ42 protein aggregation and effective disaggregation of mature Aβ42 fibrils in vitro.
• The synthesized material efficiently scavenged ROS, addressing oxidative stress associated with AD.
• In vivo studies confirmed that CDs@TGM-IL can cross the BBB and improve cognitive performance in AD mice.
• CDs@TGM-IL exhibited excellent biocompatibility.

Conclusions:

• CDs@TGM-IL presents a dual-action therapeutic strategy for Alzheimer's disease by targeting both Aβ aggregation and oxidative stress.
• The ability of CDs@TGM-IL to cross the BBB and its biocompatibility suggest its potential as a viable treatment for AD.